Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 6/2011

01-12-2011 | Genetics (Jose C. Florez, Section Editor)

Genetics of the HLA Region in the Prediction of Type 1 Diabetes

Authors: Janelle A. Noble, Ana M. Valdes

Published in: Current Diabetes Reports | Issue 6/2011

Login to get access

Abstract

Type 1 diabetes (T1D) is one of the most widely studied complex genetic disorders, and the genes in HLA are reported to account for approximately 40–50% of the familial aggregation of T1D. The major genetic determinants of this disease are polymorphisms of class II HLA genes encoding DQ and DR. The DR-DQ haplotypes conferring the highest risk are DRB1*03:01-DQA1*05:01-DQB1*02:01 (abbreviated “DR3”) and DRB1*04:01/02/04/05/08-DQA1*03:01-DQB1*03:02/04 (or DQB1*02; abbreviated “DR4”). The risk is much higher for the heterozygote formed by these two haplotypes (OR = 16.59; 95% CI, 13.7–20.1) than for either of the homozygotes (DR3/DR3, OR = 6.32; 95% CI, 5.12–7.80; DR4/DR4, OR = 5.68; 95% CI, 3.91). In addition, some haplotypes confer strong protection from disease, such as DRB1*15:01-DQA1*01:02-DQB1*06:02 (abbreviated “DR2”; OR = 0.03; 95% CI, 0.01–0.07). After adjusting for the genetic correlation with DR and DQ, significant associations can be seen for HLA class II DPB1 alleles, in particular, DPB1*04:02, DPB1*03:01, and DPB1*02:02. Outside of the class II region, the strongest susceptibility is conferred by class I allele B*39:06 (OR =10.31; 95% CI, 4.21–25.1) and other HLA-B alleles. In addition, several loci in the class III region are reported to be associated with T1D, as are some loci telomeric to class I. Not surprisingly, current approaches for the prediction of T1D in screening studies take advantage of genotyping HLA-DR and HLA-DQ loci, which is then combined with family history and screening for autoantibodies directed against islet-cell antigens. Inclusion of additional moderate HLA risk haplotypes may help identify the majority of children with T1D before the onset of the disease.
Literature
1.
• Eisenbarth GS: Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 2010, 59:759–774. This lecture gives an excellent overview of T1D pathogenesis important to the understanding of the genetic susceptibility. PubMedCrossRef
2.
Dunger DB, Sperling MA, Acerini CL, Bohn DJ, Daneman D, Danne TP, et al. European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents. Pediatrics. 2004;113:e133–40.PubMedCrossRef
3.
Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39:481–97.PubMedCrossRef
4.
Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care. 2000;23:1516–26.PubMedCrossRef
5.
Dabelea D, Bell RA, D'Agostino Jr RB, Imperatore G, Johansen JM, Linder B, et al. Incidence of diabetes in youth in the United States. Jama. 2007;297:2716–24.PubMedCrossRef
6.
7.
Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med. 2008;359:2849–50.PubMedCrossRef
8.
Bonifacio E, Ziegler AG. Advances in the prediction and natural history of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39:513–25.PubMedCrossRef
9.
Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996;59:1134–48.PubMed
10.
Lambert AP, Gillespie KM, Thomson G, Cordell HJ, Todd JA, Gale EA, et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab. 2004;89:4037–43.PubMedCrossRef
11.
Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, et al. Gene map of the extended human MHC. Nat Rev Genet. 2004;5:889–99.PubMedCrossRef
12.
Thomson G, Valdes AM, Noble JA, Kockum I, Grote MN, Najman J, et al. Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens. 2007;70:110–27.PubMedCrossRef
13.
14.
Singal DP, Blajchman MA. Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes. 1973;22:429–32.PubMed
15.
16.
Payami H, Thomson G, Motro U, Louis EJ, Hudes E. The affected sib method. IV. Sib trios. Ann Hum Genet. 1985;49:303–14.PubMedCrossRef
17.
Thomson G, Robinson WP, Kuhner MK, Joe S, MacDonald MJ, Gottschall JL, et al. Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am J Hum Genet. 1988;43:799–816.PubMed
18.
•• Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, Todd JA, Bonella P, Fear AL, Lavant E, Louey A, Moonsamy P: HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk: Analysis of the Type 1 Diabetes Genetics Consortium Families. Diabetes 2008, 57:1084–1092. This paper summarizes the analyses of HLA class II DR- and DQ-encoding genes on T1D risk in the T1DGC samples. PubMedCrossRef
19.
Robinson WP, Barbosa J, Rich SS, Thomson G. Homozygous parent affected sib pair method for detecting disease predisposing variants: application to insulin dependent diabetes mellitus. Genet Epidemiol. 1993;10:273–88.PubMedCrossRef
20.
Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature. 2007;450:887–92.PubMedCrossRef
21.
Thomson G. HLA DR antigens and susceptibility to insulin-dependent diabetes mellitus. Am J Hum Genet. 1984;36:1309–17.PubMed
22.
Noble JA, Valdes AM, Bugawan TL, Apple RJ, Thomson G, Erlich HA. The HLA class I A locus affects susceptibility to type 1 diabetes. Hum Immunol. 2002;63:657–64.PubMedCrossRef
23.
Svejgaard A, Ryder LP. HLA and insulin-dependent diabetes: an overview. Genet Epidemiol. 1989;6:1–14.PubMedCrossRef
24.
Ronningen KS, Markussen G, Iwe T, Thorsby E. An increased risk of insulin-dependent diabetes mellitus (IDDM) among HLA-DR4, DQw8/DRw8, DQw4 heterozygotes. Hum Immunol. 1989;24:165–73.PubMedCrossRef
25.
Valdes AM, Thomson G, Graham J, Zarghami M, McNeney B, Kockum I, et al. D6S265*15 marks a DRB1*15, DQB1*0602 haplotype associated with attenuated protection from type 1 diabetes mellitus. Diabetologia. 2005;48:2540–3.PubMedCrossRef
26.
Pawelec G, Buhring HJ. Expression of MHC class II epitopes on human T lymphocyte clones. Cell Immunol. 1990;127:520–6.PubMedCrossRef
27.
Cesbron A, Moreau P, Milpied N, Harousseau JL, Muller JY, Bignon JD. Crucial role of the third and fourth hypervariable regions of HLA-DPB1 allelic sequences in the mixed lymphocyte reaction. Hum Immunol. 1992;33:202–7.PubMedCrossRef
28.
Nicholson I, Varney M, Kanaan C, Grigg A, Szer J, Tiedemann K, et al. Alloresponses to HLA-DP detected in the primary MLR: correlation with a single amino acid difference. Hum Immunol. 1997;55:163–9.PubMedCrossRef
29.
Begovich AB, Bugawan TL, Nepom BS, Klitz W, Nepom GT, Erlich HA. A specific HLA-DP beta allele is associated with pauciarticular juvenile rheumatoid arthritis but not adult rheumatoid arthritis. Proc Natl Acad Sci U S A. 1989;86:9489–93.PubMedCrossRef
30.
Rosenman KD, Rossman M, Hertzberg V, Reilly MJ, Rice C, Kanterakis E, et al. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity. Occup Environ Med. 2011;68:487–93.PubMedCrossRef
31.
Cruz TD, Valdes AM, Santiago A, Frazer De Llado T, Raffel LJ, Zeidler A. DPB1 alleles are associated with type 1 diabetes susceptibility in multiple ethnic groups. Diabetes. 2004;53:2158–63.PubMedCrossRef
32.
Al-Hussein KA, Rama NR, Ahmad M, Rozemuller E, Tilanus MG. HLA-DPB1*0401 is associated with dominant protection against type 1 diabetes in the general Saudi population and in subjects with a high-risk DR/DQ haplotype. Eur J Immunogenet. 2003;30:115–9.PubMedCrossRef
33.
Cucca F, Dudbridge F, Loddo M, Mulargia AP, Lampis R, Angius E, et al. The HLA-DPB1–associated component of the IDDM1 and its relationship to the major loci HLA-DQB1, -DQA1, and -DRB1. Diabetes. 2001;50:1200–5.PubMedCrossRef
34.
Noble JA, Valdes AM, Thomson G, Erlich HA. The HLA class II locus DPB1 can influence susceptibility to type 1 diabetes. Diabetes. 2000;49:121–5.PubMedCrossRef
35.
Nishimaki K, Kawamura T, Inada H, Yagawa K, Nose Y, Nabeya N, et al. HLA DPB1*0201 gene confers disease susceptibility in Japanese with childhood onset Type I diabetes, independent of HLA-DR and DQ genotypes. Diabetes Res Clin Pract. 2000;47:49–55.PubMedCrossRef
36.
Erlich HA, Rotter JI, Chang JD, Shaw SD, Raffel LJ, Klitz W, et al. Association of HLA-DPB1*0301 with insulin dependent diabetes mellitus in Mexican-Americans. Diabetes. 1996;45:610–4.PubMedCrossRef
37.
Balducci-Silano PL, Layrisse ZE. HLA-DP and susceptibility to insulin-dependent diabetes mellitus in an ethnically mixed population. Associations with other HLA-alleles. J Autoimmun. 1995;8:425–37.PubMedCrossRef
38.
Baisch JM, Capra JD. Analysis of HLA genotypes and susceptibility to insulin-dependent diabetes mellitus: association maps telomeric to HLA-DP. Scand J Immunol. 1992;36:331–40.PubMedCrossRef
39.
Johansson S, Lie BA, Pociot F, Nerup J, Cambon-Thomsen A, Kockum I, et al. HLA associations in type 1 diabetes: DPB1 alleles may act as markers of other HLA-complex susceptibility genes. Tissue Antigens. 2003;61:344–51.PubMedCrossRef
40.
Lie BA, Akselsen HE, Joner G, Dahl-Jorgensen K, Ronningen KS, Thorsby E, et al. HLA associations in insulin-dependent diabetes mellitus: no independent association to particular DP genes. Hum Immunol. 1997;55:170–5.PubMedCrossRef
41.
Mbanya JC, Sobngwi E, Mbanya DN. HLA-DRB1, -DQA1, -DQB1 and DPB1 susceptibility alleles in Cameroonian type 1 diabetes patients and controls. Eur J Immunogenet. 2001;28:459–62.PubMedCrossRef
42.
• Varney MD, Valdes AM, Carlson JA, Noble JA, Tait BD, Bonella P, Lavant E, Fear AL, Louey A, Moonsamy P, Mychaleckyj JC, Erlich H: HLA DPA1, DPB1 alleles and haplotypes contribute to the risk associated with type 1 diabetes: analysis of the type 1 diabetes genetics consortium families. Diabetes 2010, 59:2055–2062. This paper summarizes the results of T1D association analyses of the HLA class II genes encoding the DP molecule in the T1DGC samples. PubMedCrossRef
43.
Serreze DV, Holl TM, Marron MP, Graser RT, Johnson EA, Choisy-Rossi C, et al. MHC class II molecules play a role in the selection of autoreactive class I-restricted CD8 T cells that are essential contributors to type 1 diabetes development in nonobese diabetic mice. J Immunol. 2004;172:871–9.PubMed
44.
Inoue K, Ikegami H, Fujisawa T, Noso S, Nojima K, Babaya N, et al. Allelic variation in class I K gene as candidate for a second component of MHC-linked susceptibility to type 1 diabetes in non-obese diabetic mice. Diabetologia. 2004;47:739–47.PubMedCrossRef
45.
Nakanishi K, Kobayashi T, Murase T, Naruse T, Nose Y, Inoko H. Human leukocyte antigen-A24 and -DQA1*0301 in Japanese insulin-dependent diabetes mellitus: independent contributions to susceptibility to the disease and additive contributions to acceleration of beta-cell destruction. J Clin Endocrinol Metab. 1999;84:3721–5.PubMedCrossRef
46.
•• Noble JA, Valdes AM, Varney MD, Carlson JA, Moonsamy P, Fear AL, Lane JA, Lavant E, Rappner R, Louey A, Concannon P, Mychaleckyj JC, Erlich HA: HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. Diabetes 2010, 59:2972–2979. This paper describes the results of T1D association for HLA class I A, B, and C genes from the T1DGC samples. PubMedCrossRef
47.
Valdes AM, Erlich HA, Noble JA. Human leukocyte antigen class I B and C loci contribute to Type 1 Diabetes (T1D) susceptibility and age at T1D onset. Hum Immunol. 2005;66:301–13.PubMedCrossRef
48.
Baschal EE, Baker PR, Eyring KR, Siebert JC, Jasinski JM, Eisenbarth GS. The HLA-B*3906 allele imparts a high risk of diabetes only on specific HLA-DR/DQ haplotypes. Diabetologia. 2011;54:1702–9.PubMedCrossRef
49.
Cucca F, Lampis R, Frau F, Macis D, Angius E, Masile P, et al. The distribution of DR4 haplotypes in Sardinia suggests a primary association of type I diabetes with DRB1 and DQB1 loci. Hum Immunol. 1995;43:301–8.PubMedCrossRef
50.
Cucca F, Muntoni F, Lampis R, Frau F, Argiolas L, Silvetti M, et al. Combinations of specific DRB1, DQA1, DQB1 haplotypes are associated with insulin-dependent diabetes mellitus in Sardinia. Hum Immunol. 1993;37:85–94.PubMedCrossRef
51.
52.
Johansson S, Lie BA, Todd JA, Pociot F, Nerup J, Cambon-Thomsen A, et al. Evidence of at least two type 1 diabetes susceptibility genes in the HLA complex distinct from HLA-DQB1, -DQA1 and -DRB1. Genes Immun. 2003;4:46–53.PubMedCrossRef
53.
Noble JA, Valdes AM, Lane JA, Green AE, Erlich HA. Linkage disequilibrium with predisposing DR3 haplotypes accounts for apparent effects of tumor necrosis factor and lymphotoxin-alpha polymorphisms on type 1 diabetes susceptibility. Hum Immunol. 2006;67:999–1004.PubMedCrossRef
54.
Eike MC, Olsson M, Undlien DE, Dahl-Jorgensen K, Joner G, Ronningen KS, et al. Genetic variants of the HLA-A, HLA-B and AIF1 loci show independent associations with type 1 diabetes in Norwegian families. Genes Immun. 2009;10:141–50.PubMedCrossRef
55.
Valdes AM, Arden NK, Tamm A, Kisand K, Doherty S, Pola E, et al. A meta-analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis. Osteoarthritis Cartilage. 2010;18:699–704.PubMedCrossRef
56.
Roach JC, Deutsch K, Li S, Siegel AF, Bekris LM, Einhaus DC, et al. Genetic mapping at 3-kilobase resolution reveals inositol 1,4,5-triphosphate receptor 3 as a risk factor for type 1 diabetes in Sweden. Am J Hum Genet. 2006;79:614–27.PubMedCrossRef
57.
Qu HQ, Marchand L, Szymborski A, Grabs R, Polychronakos C. The association between type 1 diabetes and the ITPR3 gene polymorphism due to linkage disequilibrium with HLA class II. Genes Immun. 2008;9:264–6.PubMedCrossRef
58.
Aly TA, Baschal EE, Jahromi MM, Fernando MS, Babu SR, Fingerlin TE, et al. Analysis of single nucleotide polymorphisms identifies major type 1A diabetes locus telomeric of the major histocompatibility complex. Diabetes. 2008;57:770–6.PubMedCrossRef
59.
Viken MK, Blomhoff A, Olsson M, Akselsen HE, Pociot F, Nerup J, et al. Reproducible association with type 1 diabetes in the extended class I region of the major histocompatibility complex. Genes Immun. 2009;10:323–33.PubMedCrossRef
60.
Bossuyt P. In Evidence-based laboratory medicine: principles, practice, and outcomes Washington, DC, USA, AACC Press, 2007, p. 67–81.
61.
Clayton DG. Prediction and interaction in complex disease genetics: experience in type 1 diabetes. PLoS Genet. 2009;5:e1000540.PubMedCrossRef
62.
Aly TA, Ide A, Humphrey K, Barker JM, Steck A, Erlich HA, Yu L, Miao D, Redondo MJ, McFann K, Roberts CM, Babu SR, Norris JM, Eisenbarth GS, Rewers MJ: Genetic prediction of autoimmunity: initial oligogenic prediction of anti-islet autoimmunity amongst DR3/DR4-DQ8 relatives of patients with type 1A diabetes. J Autoimmun 25 2005, Suppl:40–45.
63.
Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A. 2006;103:14074–9.PubMedCrossRef
64.
Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598–608.PubMedCrossRef
65.
Cucca F, Lampis R, Congia M, Angius E, Nutland S, Bain SC, et al. A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. Hum Mol Genet. 2001;10:2025–37.PubMedCrossRef
66.
Petrone A, Bugawan TL, Mesturino CA, Nistico L, Galgani A, Giorgi G, et al. The distribution of HLA class II susceptible/protective haplotypes could partially explain the low incidence of type 1 diabetes in continental Italy (Lazio region). Tissue Antigens. 2001;58:385–94.PubMedCrossRef
67.
Pugliese A, Dorman JS, Steenkiste A. The 13th International Histocompatibility Working Group for Type 1 Diabetes (T1D) Joint Report. In: Hanson JA, editor. 13th International Histocompatibility Workshop and Conference. Seattle: IHWG Press; 2007. p. 788–96.
68.
Hermann R, Turpeinen H, Laine AP, Veijola R, Knip M, Simell O, et al. HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens. 2003;62:162–9.PubMedCrossRef
69.
Hermann R, Mijovic CH, Rayner M, Croft N, Kelly MA, Jenkins D, et al. HLA alleles and IDDM in children in Hungary: a comparison with Finland. Hum Immunol. 2001;62:391–8.PubMedCrossRef
70.
Petrone A, Battelino T, Krzisnik C, Bugawan T, Erlich H, Di Mario U, et al. Similar incidence of type 1 diabetes in two ethnically different populations (Italy and Slovenia) is sustained by similar HLA susceptible/protective haplotype frequencies. Tissue Antigens. 2002;60:244–53.PubMedCrossRef
71.
Saruhan-Direskeneli G, Uyar FA, Bas F, Gunoz H, Bundak R, Saka N, et al. HLA-DR and -DQ associations with insulin-dependent diabetes mellitus in a population of Turkey. Hum Immunol. 2000;61:296–302.PubMedCrossRef
72.
Chang YW, Lam KS, Hawkins BR. Strong association between DQA1/DQB1 genotype and early-onset IDDM in Chinese: the association is with alleles rather than specific residues. Eur J Immunogenet. 1998;25:273–80.PubMedCrossRef
73.
Chan SH, Thai AC, Lin YN, Liu KF, Wee GB. Influence of gender and age at onset on the HLA associations in Chinese with insulin-dependent diabetes mellitus. Hum Immunol. 1995;44:175–80.PubMedCrossRef
74.
Bugawan TL, Klitz W, Alejandrino M, Ching J, Panelo A, Solfelix CM, et al. The association of specific HLA class I and II alleles with type 1 diabetes among Filipinos. Tissue Antigens. 2002;59:452–69.PubMedCrossRef
75.
Erlich HA, Zeidler A, Chang J, Shaw S, Raffel LJ, Klitz W, et al. HLA class II alleles and susceptibility and resistance to insulin dependent diabetes mellitus in Mexican-American families. Nat Genet. 1993;3:358–64.PubMedCrossRef
Metadata
Title
Genetics of the HLA Region in the Prediction of Type 1 Diabetes
Authors
Janelle A. Noble
Ana M. Valdes
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 6/2011
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-011-0223-x

Other articles of this Issue 6/2011

Current Diabetes Reports 6/2011 Go to the issue

Clinical Trial Report

Does Metformin Work for Everyone? A Genome-wide Association Study for Metformin Response

Genetics (Jose C. Florez, Section Editor)

The Molecular Genetics of Sulfonylurea Receptors in the Pathogenesis and Treatment of Insulin Secretory Disorders and Type 2 Diabetes

Psychosocial Aspects (Korey Hood, Section Editor)

Methodological Issues in the Assessment of Diabetes Treatment Adherence

Psychosocial Aspects (Korey Hood, Section Editor)

Building a Pipeline of Training for Behavioral Diabetes Researchers and Clinicians: A Call for National Dialogue

Psychosocial Aspects (Korey Hood, Section Editor)

Family Interaction in Pediatric Diabetes

Letter to the Editor

Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate is Not yet Closed
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits